menin

Menin-MLL inhibitor MI-2 (MI2) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM.

Menin-MLL inhibitor 20 is an irreversible inhibitor of the menin-MLL interaction, exhibiting antitumor activities.

Menin-MLL Inhibitor 29 (Compound C1) is a Menin-MLL protein-protein interaction (PPI) inhibitor that demonstrates high affinity to Menin with a dissociation constant (K D) of 138 nM and impedes Menin's interaction with Menin-binding motif 1 (MBM1), as evidenced by an inhibition constant (IC 50) of 46 nM. Additionally, it exhibits anti-proliferative activity against HepG2 and Hep3B hepatoma cell lines with IC 50 values of 0.31 μM and 0.71 μM, respectively, and has been shown to inhibit tumor growth [1].

(1s,4s)-Menin-MLL Inhibitor-23, an enantiomer of Menin-MLL Inhibitor-23 (Example 99A), functions as an inhibitor of the menin-MLL interaction [1].

Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction .

Menin-MLL inhibitor 27 effectively inhibits the interaction between Menin and MLL, serving as a potential tool in cancer research, particularly for acute myeloid leukemia (AML) [1].

Menin-MLL inhibitor 26 is a Menin-MLL inhibitor. Menin-MLL inhibitor 26 also is an active reference. Menin-MLL inhibitor 26 can inhibits cell growth. Menin-MLL inhibitor 26 can be used for the research of leukemia .

Menin-MLL inhibitor 31 (compound 18) effectively disrupts the menin-MLL interaction, demonstrating a potent IC 50 value of 4.6 nM [1].

Sinomenine (Kukoline) is a pure alkaloid isolated from the Sinomenium acutum, is utilized in the treatment of rheumatism and arthritis.

Sinomenine hydrochloride (Kukoline hydrochloride) is extracted from Sinomenium Acutum Rehderett Wilson.

Menin-MLL Inhibitor 24 (compound A) oxalate, a menin-mixed-lineage leukemia 1 (menin-MLL) inhibitor, is utilized in cancer research [1].

MI-3 (Menin-MLL Inhibitor) (Menin-MLL Inhibitor) is an effective inhibitor of Menin-MLL interaction (IC50: 648 nM).

SNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM). SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias.

MIV-6R inhibits Menin-MLL interaction (IC50: 56 nM) and can be used to study leukemia.

Chamaejasmenin B is a compound isolated from Stellera chamaejasme L. Chamaejasmenin B has anticancer and antitumor activity, inhibiting cancer cell migration and invasion, and inhibiting tumor metastasis.Chamaejasmenin B is used in the study of cancers such as breast cancer.

14,15-Didehydrovincamenine is a natural product for research related to life sciences. The catalog number is TN2620 and the CAS number is 112219-48-4.

Chamaejasmenin D is a useful organic compound for research related to life sciences and the catalog number is T124064.

14-Episinomenine, an alkaloid, can be isolated from Stephania cepharantha [1].

(-)-Neuchromenin is an inducer of neurite outgrowth of PC12 cells at concentration of 2.5-10 ug/ml.

7-Ketoisodrimenin is a natural product for research related to life sciences. The catalog number is TN5381 and the CAS number is 73036-54-1.

Plathymenin is a natural product isolated from Spatholobus suberectus.

7(R)-7,8-Dihydrosinomenine, an isoquinoline alkaloid extractable from Sinomenium acutum (Menispermaceae), exhibits anti-osteoclastogenic properties [1].

1,1′-Disinomenine, an alkaloid extracted from the stems of Sinomenium acutum, exhibits modest inhibitory activity against A549 and Hela cells [1].

Chamaejasmenin A, a C-3 C-3’’ linkage biflavanone, can be isolated from Stellera chamaejasme L. [1].

Isochamaejasmenin B is a useful organic compound for research related to life sciences and the catalog number is T124063.

Chamaejasmenin C is a natural product for research related to life sciences. The catalog number is TN3629 and the CAS number is 89595-70-0.

12-Hydroxyisodrimenin is a natural product for research related to life sciences. The catalog number is TN2599 and the CAS number is 218780-16-6.

Sinomenine N-oxide is one of the major metabolites of the cyclic metabolic mechanism of Sinomenine.

Methyl isodrimeninol is a natural product of Polygonum, Polygonaceae. The catalog number is TN4547 and the CAS number is 442851-27-6. Methyl isodrimeninol can be used as a reference standard.

MI-538 is an interaction between menin and MLL fusion proteins inhibitor(IC50 of 21 nM).

MI-463 is a potent and orally bioavailable inhibitor of the menin-mLL interaction (IC50: 15.3 nM).

Iptacopan hydrochloride hydrate is a highly potent and highly selective factor B inhibitor.

M-808 is a potent and efficacious covalent inhibitor, targeting the interaction between Menin and MLL. It demonstrates a high binding affinity with an IC50 value of 2.6 nM.

VTP50469 is a highly selective and orally active inhibitor of Menin-MLL interaction( Ki: 104 pM) and has potently anti-leukemia activity.

MI-2-2 is an inhibitor of bivalent protein-protein interaction between menin and MLL with an IC50 of 46 nM. MI-2-2 binds to menin with Kd of 22 nM.

BAY-155 is a powerful and selective menin-MLL inhibitor, exhibiting an IC 50 of 8 nM. It significantly down-regulates MEIS1 gene expression while up-regulating CD11b and MNDA genes. BAY-155 also demonstrates anti-proliferative effects in AML ALL (acute myeloid lymphoblastic leukemia) models [1].

VTP50469 fumarate is a highly selective and orally active inhibitor of Menin-MLL interaction (Ki: 104 pM), and has potently anti-leukemia activity.

MI-1481 is an effective MML1 inhibitor (IC50: 3.6 nM). MI-1481 showed very potent inhibition of the menin-MLL1 interaction (IC50: 3.6 nM). MI-1481 also demonstrates pronounced activity in MLL leukemia cells and in vivo in MLL leukemia models.

M-89, a highly potent and specific inhibitor of the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction, exhibits a Kd of 1.4 nM for menin binding. This compound holds potential for treating MLL leukemia.

ML399 is the menin-- MLL interaction inhibitor that acts by demonstrating strong and selective effects in MLL leukemia cells and validating specific mechanism of action.

M‑89 is a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein−Protein Interaction (Kd = 1.4 nM; IC50 = 25nM). M-89 binds to menin with a Kd value of 1.4 nM and effectively engages cellular menin protein at low nanomolar concentrations. M-89 inhibits cell growth in the MV4;11 and MOLM-13 leukemia cell lines carrying MLL fusion with IC50 values of 25 and 55 nM, respectively, and demonstrates >100-fold selectivity over the HL-60 leukemia cell line lacking MLL fusion.

MI-136 inhibits expression of androgen receptor (AR) target genes that DHT induced.

M 1121 is a covalent and orally active inhibitor of the menin-MLL interaction capable of achieving complete and persistent tumor regression.

MIV-6 is an inhibitor of the menin-mixed lineage leukemia interaction.

Ziftomenib (KO-539) is an inhibitor of menin-MLL interaction with antitumor activity, suitable for leukemia research.

MI-2 (Menin-MLL Inhibitor) is an effective menin-MLL interaction inhibitor (IC50: 446 ± 28 nM).

MI-503 is an efficient and selective Menin-MLL inhibitor with an IC50 of 14.7 nM. In human MLL leukemia cell lines, MI-503 has a significant growth inhibition effect (GI = 250 nM-570 nM).

MI-1 inhibits Menin-MLL interaction with an IC₅₀ of 1.9 μM [1].